CREBBP and Hepatic fibrosis: Furthermore, PRI-724’s excellent safety profile and promising on target clinical effects both in oncology and liver fibrosis bode well for specific CBP/β-catenin antagonist development, to maintain or regain lineage fidelity, commonly defective in diseases of aging including cancer, fibrosis and neurodegeneration.